Last reviewed · How we verify
Menopur (MENOTROPINS)
MENOPUR promotes ovarian follicular growth and maturation, requiring hCG for ovulation.
Menopur (menotropins) is a medication developed by Ferring, currently owned by the same company. It is used to treat ovulatory women as part of an Assisted Reproductive Technology (ART) cycle, aiming to develop multiple follicles and achieve pregnancy. Menopur is a commercial product with a patented status, approved by the FDA in 2013. Key safety considerations include potential risks of ovarian hyperstimulation syndrome (OHSS) and multiple gestations. As a commercial product, it is not yet off-patent.
At a glance
| Generic name | MENOTROPINS |
|---|---|
| Sponsor | Ferring |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2013 |
Mechanism of action
MENOPUR is used to stimulate the growth and maturation of ovarian follicles in women without primary ovarian failure. Once sufficient follicular maturation is achieved, hCG is necessary to trigger ovulation.
Approved indications
- Development of multiple follicles and pregnancy in ovulatory women
Common side effects
- abdominal cramps
- abdomen enlarged
- abdominal pain
- headache
- injection site pain + reaction
- injection site inflammation
- Ovarian Hyperstimulation Syndrome (OHSS)
Key clinical trials
- Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer. (PHASE3)
- The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles (PHASE4)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome (PHASE2)
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT (NA)
- Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menopur CI brief — competitive landscape report
- Menopur updates RSS · CI watch RSS
- Ferring portfolio CI